By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Millennium: The Takeda Oncology Company 

40 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-679-7000 Fax: 617-374-7788

About Millennium
Millennium: The Takeda Oncology Company, is a leading biopharmaceutical company based in Cambridge, Mass., Millennium was established in 1993 as a genomics company (Millennium Pharmaceuticals, Inc.) and has grown into a fully-integrated biopharmaceutical company with a pipeline of innovative molecules focused in oncology.

Our business begins and ends with the quality of our science. We take deep pride in the world class quality of both our discovery and development science (R&D). Our science has been instrumental in producing medicine that makes a real difference in patients’ lives.

Our company markets VELCADE® (bortezomib) for Injection, a leading global cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. VELCADE is co-developed by Millennium and Janssen Pharmaceutical Companies. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen Pharmaceutical Companies are responsible for commercialization in Europe and the rest of the world. Takeda Pharmaceutical Company Limited and Janssen Pharmaceutical K.K. co-promote VELCADE in Japan. VELCADE is approved in more than 90 countries and has been used to treat more than 350,000 patients worldwide.

Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.

Along with our increased capacity in oncology comes an increased accountability for success. Our goal is to become a global leader in providing medicines that fundamentally improve the lives of patients with cancer. Specifically, our aim is to be a top-three global oncology company by 2020. In the most competitive of therapeutic categories, this is an audacious goal, but one worthy of Millennium and Takeda.

Additional information about Millennium is available through its website,

Key Statistics

Ownership: Public

Web Site: Millennium: The Takeda Oncology Company
Employees: 1400




Roche (NJ)  Obesity and Type II Diabetes, Agreement signed in March 1994, $50 Million plus milestone payments

Astra AB  Respiratory Inflammation, Agreement signed in December 1995, $53 Million plus milestone payments

Wyeth Pharmaceuticals (Pennsylvania)  Central Nervous System (CNS), Agreement signed in July 1996, $90 million plus milestone payments

Wyeth Pharmaceuticals (Pennsylvania)  Bacterial Diseases, Agreement signed in December 1996, $20 million plus milestone payments

Lexicon Genetics Incorporated 

Searle  Gained access to proprietary genomics technologies

Bayer Pharmaceuticals Corporation (CT)  Genomics Alliance

ILEX Oncology, Inc.  Development of CAMPATH.

Company News
Millennium: The Takeda Oncology Company Release: FDA Approves VELCADE® (Bortezomib) For Injection For Previously Untreated Patients With Mantle Cell Lymphoma 10/9/2014 11:12:50 AM
Millennium: The Takeda Oncology Company Release: FDA Approves VELCADE® (Bortezomib) Retreatment In Patients With Multiple Myeloma 8/11/2014 8:44:10 AM
Ex-Millennium: The Takeda Oncology Company CEO to Head EnVivo Pharmaceuticals, Inc. 7/11/2013 7:15:42 AM
Millennium: The Takeda Oncology Company Release: Meta-Analysis of VELCADE® (bortezomib)-Based Induction Therapy Followed by Stem-Cell Transplantation Showed Significantly Greater Response and Longer Progression-Free and Overall Survival in Patients With Multiple Myeloma 4/8/2013 10:21:36 AM
Millennium: The Takeda Oncology Company and the WIN Consortium Become Partners in the Fight Against Cancer 3/29/2013 10:11:18 AM
Seattle Genetics, Inc. (SGEN) and Millennium: The Takeda Oncology Company Initiate Global Phase III Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL) 1/24/2013 9:38:36 AM
Multiple Myeloma Research Foundation (MMRF) Names Millennium: The Takeda Oncology Company Collaborator of the Year 1/23/2013 9:23:34 AM
Infinity Pharmaceuticals Inc. (INFI) Pays Millennium: The Takeda Oncology Company $15 Million 12/27/2012 7:41:15 AM
Millennium: The Takeda Oncology Company Reports Positive Velcade Trial Data 12/10/2012 7:35:02 AM
VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium: The Takeda Oncology Company Pipeline Agents to be Featured at American Society of Hematology Annual Meeting 11/6/2012 7:44:55 AM